The use of the Ki-67 marker in the pathological diagnosis of the epithelioid variant of renal angiomyolipoma
- First Online:
- 148 Downloads
Epithelioid angiomyolipoma (EAML) is a rare malignant variant of renal angiomyolipoma (AML). There were 34 cases of EAML reported in 25 studies (including this present study) over the past decade. About 68% were females and 32% males. The mean age was 40.1 years, 53% developed metastatic disease after nephrectomy, and eight patients had TSC. All cases are reported positive when stained with HMB-45 which also labels all classical AML. This study evaluates the use of Ki-67 (proliferation marker) in the pathological diagnosis of EAML and distinction from classical AML.
Immunohistochemical reactions for Ki-67 were generated on multiple representative blocks of tissue obtained from two cases of HMB-45 positive EAML and four cases of classic AML and the percentage of positively staining cells estimated.
Both cases of EAML were strongly positive for Ki-67 while all four classic AML were completely negative.
The Ki67 is a useful marker in which distinguishes the malignant epithelioid variant of AML from classic AML.
KeywordsEpithelioid variant Renal angiomyolipoma Renal Ki-67 Proliferative marker
- 1.Neumann H, Henske E, Iliopoulos O et al (2005) Renal involvement in tuberous sclerosis and von Hippel-Lindau disease. In: Davison A, Cameron J, Grunfeld J (eds) Oxford Textbook of Clinical Nephrology, 3rd edn. Oxford University Press, New York, pp 2397–2401Google Scholar
- 16.Oesterling JE, Fishman EK, Goldman SM et al (1996) The management of renal angiomyolipoma. J Urol 131:1121Google Scholar
- 20.Jarzabek K, Koda M, Kozlowski L et al (2005) Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 41:2924–2934PubMedCrossRefGoogle Scholar
- 22.Quek ML, Rashida AS, Hsu J et al (2005) Renal epithelioid angiomyolipoma associated with hyperprolactinemia. Urology 65:797.e1–797.e2Google Scholar